Lunai Bioworks Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lunai Bioworks Inc (LNAI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Lunai Bioworks Inc vs Its Competitors
- Profitability: Its -6,475.7% net margin compares with 15.9% for the peer group.
- Peer revenue share: Lunai Bioworks Inc accounted for 0.0% of combined revenue among its tracked peer group.
- Structure: Lunai Bioworks Inc operates in the following segments: Bio Symetrics, RENB.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LNAI Sales vs. its Competitors, Q4 2026
With a net margin of -6,475.69 %, Lunai Bioworks Inc reported lower profitability than its competitors (15.94 %).
Lunai Bioworks Inc generated 0.00 % of the combined sales of its peer group.
API endpoints for this dataset
Lunai Bioworks Inc vs. its Competitors, Q4 2026
Net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Lunai Bioworks Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Lunai Bioworks Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Lunai Bioworks Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Lunai Bioworks Inc's competitor groups requires a Commercial License.
Lunai Bioworks Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lunai Bioworks Inc | - | - | - | No |
| Competitors combined (49) | ||||
| High-Confidence Competitors (16) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LNAI Stock Performance relative to its Competitors
LNAI Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 2 | Longeveron Inc | 282.9% | Outperformed |
| 3 | Exact Sciences Corporation | 282.9% | Outperformed |
| 4 | Ovid Therapeutics Inc | 282.9% | Outperformed |
| 5 | Boundless Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Lunai Bioworks Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Lunai Bioworks Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Lunai Bioworks Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Lunai Bioworks Inc |
5.55 | - |
 Amgen Inc |
254,015.58 | 38,903.00 |
 Bristol myers Squibb Company |
128,928.40 | 50,033.00 |
 Regeneron Pharmaceuticals Inc |
96,735.94 | 16,896.20 |
 Teva Pharmaceutical Industries Limited |
50,159.20 | 14,020.00 |
 Beone Medicines Ltd |
48,431.86 | 6,606.28 |
| SUBTOTAL | 655,777.90 | 148,028.24 |
Sign in to see all competitors of Lunai Bioworks Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Lunai Bioworks Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Lunai Bioworks Inc's Competitors Named by the Company
Competitive relationships identified from Lunai Bioworks Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Exact Sciences Corporation | Company report | 85% |
| Grail, Inc. | Company report | 85% |
| Recursion Pharma | Company report | 85% |
| In Silico Medicine | Company report | 85% |
| insitro | Company report | 85% |
| Thrive Earlier Detection Corp. | Company report | 85% |
| Freenome, Inc. | Company report | 85% |
| Iovance Biotechnologies, Inc. | Company report | 85% |
| uniQure N.V. | Company report | 85% |
| Cellectis S.A. | Company report | 85% |
| Novartis AG | Company report | 85% |
| Shire | Company report | 85% |
| Atara Biotherapeutics, Inc. | Company report | 85% |
| GlaxoSmithKline plc | Company report | 85% |
| Juno Therapeutics, Inc. | Company report | 85% |
| Regenxbio Inc. | Company report | 85% |
| Pfizer | Company report | 85% |
| bluebird bio, Inc. | Company report | 85% |
| Kite Pharma | Company report | 85% |
| Sangamo | Company report | 85% |
| Adaptimmune Therapeutics PLC | Company report | 85% |
| Molecular Data Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Lunai Bioworks Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Lunai Bioworks Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Lunai Bioworks Inc | Bio Symetrics 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 59.34 % |
| Grail Inc | Reportable 100.00 % |
| Mannkind Corporation | All Other Segments 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Lunai Bioworks Inc .
Lunai Bioworks Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Lunai Bioworks Inc | 6 | - | - |
| Amgen Inc | 254,016 | 2,992,538 | 722,385 |
| Bristol myers Squibb Company | 128,928 | 1,539,477 | 284,338 |
| Regeneron Pharmaceuticals Inc | 96,736 | 1,096,444 | 312,615 |
| Teva Pharmaceutical Industries Limited | 50,159 | 412,960 | 14,963 |
| Beone Medicines Ltd | 48,432 | 550,523 | 76,298 |
| PEERS TOTAL | 655,772 | 978,220 | 146,741 |
Sign in to see all peers for Lunai Bioworks Inc .
Lunai Bioworks Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Bristol myers Squibb Company | United States 69.43 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Beone Medicines Ltd | United States 54.39 % |
| Exact Sciences Corporation | United States 93.11 % |
| Therapeuticsmd Inc | Non Us 66.30 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Lunai Bioworks Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 491 companies in Lunai Bioworks Inc's industry classification, broader than the peer set above. Market cap in millions of $.Lunai Bioworks Inc ranks #0 of 491 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 988, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,038 | 23.96 % |
| 2 | Johnson and Johnson | 685,131 | 12.82 % |
| 3 | Abbvie Inc | 520,479 | 9.74 % |
| 4 | Merck and Co Inc | 365,659 | 6.84 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Lunai Bioworks Inc | 6 | 0.00 % |
Market cap and industry share for the rest of Lunai Bioworks Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-29.
Lunai Bioworks Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (446 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.5x | - |
| EV / EBITDA | - | 15.4x | - |
| P/B | -7.0x | 4.2x | -11.2x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -9.78 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Lunai Bioworks Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - |
| Return on Invested Capital | -122.62 % | -3.27 % | -5.57 % | -3.76 % | -8.97 % | -39.09 % | -55.06 % | -649.90 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Lunai Bioworks Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 988 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Lunai Bioworks Inc's dedicated Suppliers and Customers pages, not here.
Lunai Bioworks Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Lunai Bioworks Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Lunai Bioworks Inc | 0.06 | 0.09 | - |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
| Teva Pharmaceutical Industries Limited | 0.26 | 0.96 | 2.09 |
| Beone Medicines Ltd | 2.58 | 3.50 | 0.21 |
Sign in to see all peers for Lunai Bioworks Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Lunai Bioworks Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Lunai Bioworks Inc | Q2 2026 | - | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -1.9 % | -46.3 % |
| Beone Medicines Ltd | Q2 2026 | +33.9 % | +208.2 % |
| PEERS TOTAL | +11.4 % | +31.4 % |
Sign in to see all peers for Lunai Bioworks Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Lunai Bioworks Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Lunai Bioworks Inc | Q2 2026 | - | - |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
| Teva Pharmaceutical Industries Limited | Q3 2026 | -10.2 % | +200.0 % |
| Beone Medicines Ltd | Q2 2026 | +10.7 % | -26.8 % |
Sign in to see all peers for Lunai Bioworks Inc .
Lunai Bioworks Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Lunai Bioworks Inc | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
| Teva Pharmaceutical Industries Limited | 1.26% | 1.96% | 6.37% |
| Beone Medicines Ltd | 10.23% | 13.17% | 18.21% |
Sign in to see all peers for Lunai Bioworks Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Lunai Bioworks Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Lunai Bioworks Inc | - | - |
| Amgen Inc | 26.97 | 6.53 |
| Bristol myers Squibb Company | 13.92 | 2.58 |
| Regeneron Pharmaceuticals Inc | 20.26 | 5.73 |
| Teva Pharmaceutical Industries Limited | 56.79 | 3.58 |
| Beone Medicines Ltd | 54.32 | 7.33 |
| PEERS AVERAGE | 29.54 | 4.43 |
Sign in to see all peers for Lunai Bioworks Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.